Case Commentary: Uncertainty in Evaluating Treatment Outcomes in Carbapenem-Resistant Acinetobacter baumannii Infections
| Autor: | Jessica Howard-Anderson, David van Duin |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Acinetobacter baumannii
medicine.medical_specialty animal structures Treatment outcome Microbial Sensitivity Tests law.invention Randomized controlled trial law Challenging Clinical Case in Antimicrobial Resistance Internal medicine polycyclic compounds medicine Humans Pharmacology (medical) Pharmacology biology business.industry Optimal treatment Uncertainty food and beverages Sulbactam biochemical phenomena metabolism and nutrition Acinetobacter biology.organism_classification medicine.disease Anti-Bacterial Agents body regions Pneumonia Treatment Outcome Infectious Diseases Carbapenems Carbapenem resistant Acinetobacter baumannii business Acinetobacter Infections medicine.drug |
| Zdroj: | Antimicrob Agents Chemother |
| ISSN: | 1098-6596 0066-4804 |
| DOI: | 10.1128/aac.01424-21 |
| Popis: | Carbapenem-resistant Acinetobacter baumannii (CRAB) infections are challenging to treat and associated with poor clinical outcomes. In this issue, sulbactam-durlobactam, a novel β-lactam-β-lactamase inhibitor, was used with cefiderocol to successfully treat CRAB pneumonia. While this report and in vitro data are encouraging, determining the impact of treatment regimens on clinical outcomes after CRAB infections is not straightforward. Therefore, careful evaluation in pathogen-directed randomized controlled trials is needed to determine the optimal treatment of CRAB infections. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|